JP2023535443A5 - - Google Patents
Info
- Publication number
- JP2023535443A5 JP2023535443A5 JP2023504620A JP2023504620A JP2023535443A5 JP 2023535443 A5 JP2023535443 A5 JP 2023535443A5 JP 2023504620 A JP2023504620 A JP 2023504620A JP 2023504620 A JP2023504620 A JP 2023504620A JP 2023535443 A5 JP2023535443 A5 JP 2023535443A5
- Authority
- JP
- Japan
- Prior art keywords
- complex
- antibody
- composition
- molecular payload
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055721P | 2020-07-23 | 2020-07-23 | |
| US63/055,721 | 2020-07-23 | ||
| US202063069071P | 2020-08-23 | 2020-08-23 | |
| US63/069,071 | 2020-08-23 | ||
| US202163143825P | 2021-01-30 | 2021-01-30 | |
| US63/143,825 | 2021-01-30 | ||
| PCT/US2021/040984 WO2022020105A1 (en) | 2020-07-23 | 2021-07-09 | Anti-transferrin receptor (tfr) antibody and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023535443A JP2023535443A (ja) | 2023-08-17 |
| JP2023535443A5 true JP2023535443A5 (enExample) | 2024-07-17 |
| JP7803925B2 JP7803925B2 (ja) | 2026-01-21 |
Family
ID=79729848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504620A Active JP7803925B2 (ja) | 2020-07-23 | 2021-07-09 | 抗トランスフェリン受容体（ＴｆＲ）抗体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230256112A1 (enExample) |
| EP (1) | EP4185315A4 (enExample) |
| JP (1) | JP7803925B2 (enExample) |
| KR (1) | KR20230041760A (enExample) |
| CN (1) | CN116348138A (enExample) |
| AU (1) | AU2021312708A1 (enExample) |
| BR (1) | BR112023001005A2 (enExample) |
| CA (1) | CA3186727A1 (enExample) |
| IL (1) | IL299667A (enExample) |
| MX (1) | MX2023000962A (enExample) |
| WO (1) | WO2022020105A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| MX2023000984A (es) * | 2020-07-23 | 2023-05-03 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias. |
| CN116194470B (zh) * | 2020-07-23 | 2025-10-03 | 达因疗法公司 | 肌肉靶向复合物及其用途 |
| JP2024525608A (ja) * | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| WO2023034409A1 (en) | 2021-09-01 | 2023-03-09 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| CN120659627A (zh) * | 2022-07-29 | 2025-09-16 | 瑞泽恩制药公司 | 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法 |
| CN120265319A (zh) * | 2022-09-20 | 2025-07-04 | 丹娜-法伯癌症研究院 | 受体介导的胞吞作用用于膜蛋白和货物的靶向内化和降解 |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
| TW202517685A (zh) * | 2023-10-26 | 2025-05-01 | 美商百健Ｍａ公司 | 抗運鐵蛋白受體抗體及其用途 |
| WO2025140522A1 (en) * | 2023-12-29 | 2025-07-03 | Nona Biosciences (Suzhou) Co., Ltd. | Anti-tfr1 antibodies, preparation methods and uses thereof |
| CN119192378B (zh) * | 2024-10-16 | 2025-10-17 | 中国人民解放军军事科学院军事医学研究院 | 一种pH敏感型人源抗转铁蛋白受体1抗体 |
| CN119161483B (zh) * | 2024-10-16 | 2026-02-06 | 中国人民解放军军事科学院军事医学研究院 | 人源抗转铁蛋白受体1抗体及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8734799B2 (en) * | 2010-04-13 | 2014-05-27 | The Regents Of The University Of California | Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer |
| EP3594240B1 (en) * | 2013-05-20 | 2023-12-06 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies and methods of use |
| EA039366B1 (ru) * | 2015-06-24 | 2022-01-19 | Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер |
| FR3049951A1 (fr) * | 2016-04-12 | 2017-10-13 | Univ Rabelais Francois | Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose |
| TWI869346B (zh) * | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
| WO2020028842A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating hypertrophic cardiomyopathy |
| WO2020028836A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof in treating muscle atrophy |
| IL312067B2 (en) * | 2018-12-21 | 2025-08-01 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and uses thereof |
-
2021
- 2021-07-09 KR KR1020237005829A patent/KR20230041760A/ko active Pending
- 2021-07-09 JP JP2023504620A patent/JP7803925B2/ja active Active
- 2021-07-09 CA CA3186727A patent/CA3186727A1/en active Pending
- 2021-07-09 AU AU2021312708A patent/AU2021312708A1/en active Pending
- 2021-07-09 BR BR112023001005A patent/BR112023001005A2/pt unknown
- 2021-07-09 CN CN202180064690.5A patent/CN116348138A/zh active Pending
- 2021-07-09 US US18/017,167 patent/US20230256112A1/en active Pending
- 2021-07-09 WO PCT/US2021/040984 patent/WO2022020105A1/en not_active Ceased
- 2021-07-09 IL IL299667A patent/IL299667A/en unknown
- 2021-07-09 EP EP21846109.3A patent/EP4185315A4/en active Pending
- 2021-07-09 MX MX2023000962A patent/MX2023000962A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023535443A5 (enExample) | ||
| JP2023511774A5 (enExample) | ||
| US12121527B2 (en) | Anthracycline-based antibody drug conjugates having high in vivo tolerability | |
| US12377144B2 (en) | Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen | |
| CN106029083B (zh) | 亲水性抗体-药物偶联物 | |
| JP2022513420A5 (enExample) | ||
| EP4087613A1 (en) | Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof | |
| JP2021516960A5 (enExample) | ||
| JP2012529891A5 (enExample) | ||
| JP2018532715A5 (enExample) | ||
| JP2008515889A5 (enExample) | ||
| TW201905000A (zh) | 含有抗globo h抗體之抗體－藥物共軛物及其用途 | |
| KR20250009592A (ko) | 항-가변 muc1* 항체 및 그의 용도 | |
| CN108452319A (zh) | 靶向cd20的抗体偶联药物制剂 | |
| JP2026505129A (ja) | 抗ｃｄｈ１７抗体及びその使用 | |
| CN109414509B (zh) | 使用双特异性抗体的抗体药物偶联物平台 | |
| JP2009529915A5 (enExample) | ||
| JP2025506248A5 (enExample) | ||
| IL310175A (en) | Methods for treating non-muscle invasive bladder cancer (NMIBC) with antibody-drug conjugates (ADC) that bind to 191P4D12 proteins | |
| CN1946740B (zh) | 抗人腱生蛋白单克隆抗体 | |
| TW201809013A (zh) | 用於藥物遞送之抗體融合蛋白 | |
| JP2025539702A (ja) | 肥満症を治療する方法 | |
| JP2025508389A5 (enExample) | ||
| US7615221B2 (en) | Compositions and methods for treating cancer | |
| WO2022001710A1 (zh) | 用于抗体与药物偶联体(adc)制备的中间体及其制备方法和应用 |